Schott plans to triple vial production capacity at its site in Lebanon, Pennsylvania, US.

Schott will increase its ready-to-use (RTU) vial production at its Lebanon site in a double-digit million Euro investment.

The investment will allow the company to meet the increasing demand for storing injectable drugs.

The RTU vials, known under the brand name adaptiQ, are particularly suitable for drugs such as biologics and vaccines, as well as upcoming technologies like mRNA-based drugs.

The vials are pre-washed and sterilised, and packaged in a standardised tub to simplify the filling process for pharmaceutical companies.

Andreas Reisse, Executive Vice President of SCHOTT Pharma, said: “With our investment, we are underlining our commitment to the global pharma industry and particularly the US market.

"Additionally, we are enhancing our regional manufacturing footprint in Lebanon, Pennsylvania, where we are proudly celebrating our site’s 30th anniversary.”

The adaptiQ vials are made from Fiolax Type I borosilicate glass, which is considered the 'gold standard' for packaging pharmaceuticals.

With its adaptiQ brand, Schott can provide a comprehensive product portfolio featuring more than 750 product combinations for RTU vials.

Fabian Stöcker, Vice President for the Sterile Solutions division of Schott Pharma, and Christopher Cassidy, Vice President at Schott North America, said: “The breadth of our RTU vial portfolio provides biopharma customers with the widest selection of sizes, formats, and performance capabilities. This is how we help find the proper container for the many unique and demanding drug products being developed today.”

Based on market demand, Schott is open to further expand its global production footprint for RTU vials.